The role of angiogenesis inhibitors in the management of melanoma

Current Topics in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 32-49

  Zaki, Kamarul Ahmad ^a   Basu, Bristi ^a   Corrie, Pippa ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Melanoma; Molecularly targeted therapy; Monoclonal antibodies; Tyrosine kinase inhibitors; Vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CILENGITIDE; DACARBAZINE; DOVITINIB; ENTINOSTAT; ERLOTINIB; ETARACIZUMAB; INTETUMUMAB; LIGAND; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PEGINTERFERON ALPHA2B; RAMUCIRUMAB; REGORAFENIB; ROMIDEPSIN; SEMAXANIB; SORAFENIB; SUNITINIB; TB 403; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN INHIBITOR; VATALANIB; VOLOCIXIMAB;

ANGIOGENESIS; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; FEVER; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; MELANOMA; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WOUND COMPLICATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

EID: 84855826011     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612798919240     Document Type: Article

References (183)

1. Lucas, R.; McMichael, T.; Smith, W.; Armstrong, A. Global Burden of Disease from Solar Ultraviolet Radiation Geneva: World Health Organisation, 2006.
2. MacKie, R. M.; Hauschild, A.; Eggermont, A. M. Epidemiology of invasive cutaneous melanoma. Ann. Oncol., 2009, 20(Suppl. 6), vi1-7.
3. Balch, C. M.; Gershenwald, J. E.; Soong, S. J.; Thompson, J. F.; Atkins, M. B.; Byrd, D. R.; Buzaid, A. C.; Cochran, A. J.; Coit, D. G.; Ding, S.; Eggermont, A. M.; Flaherty, K. T.; Gimotty, P. A.; Kirkwood, J. M.; McMasters, K. M.; Mihm, M. C., Jr.; Morton, D. L.; Ross, M. I.; Sober, A. J.; Sondak, V. K. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol., 2009, 27(36), 6199-6206.
4. Balch, C. M.; Buzaid, A. C.; Soong, S. J.; Atkins, M. B.; Cascinelli, N.; Coit, D. G.; Fleming, I. D.; Gershenwald, J. E.; Houghton, A., Jr.; Kirkwood, J. M.; McMasters, K. M.; Mihm, M. F.; Morton, D. L.; Reintgen, D. S.; Ross, M. I.; Sober, A.; Thompson, J. A.; Thompson, J. F. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol., 2001, 19(16), 3635-3648.
5. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
6. Ide, A.; Baker, N.; Warren, S. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol., 1939, 42, 891-899.
7. Greenblatt, M.; Shubi, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl. Cancer Inst., 1968, 41(1), 111-124.
8. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285(21), 1182-6.
9. Folkman, J.; Merler, E.; Abernathy, C.; Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med., 1971, 133(2), 275-288.
10. Folkman, J.; Klagsbrun, M. Angiogenic factors. Science, 1987, 235(4787), 442-447.
11. Lee, O. H.; Kim, Y. M.; Lee, Y. M.; Moon, E. J.; Lee, D. J.; Kim, J. H.; Kim, K. W.; Kwon, Y. G. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 1999, 264(3), 743-750.
12. Klagsbrun, M.; D'Amore, P. A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev., 1996, 7(3), 259-270.
13. Thurston, G.; Noguera-Troise, I.; Yancopoulos, G. D. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer, 2007, 7(5), 327-231.
14. Chantrain, C. F.; Henriet, P.; Jodele, S.; Emonard, H.; Feron, O.; Courtoy, P. J.; DeClerck, Y. A.; Marbaix, E. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur. J. Cancer, 2006, 42(3), 310-8.
15. Jain, R. K. Molecular regulation of vessel maturation. Nat. Med., 2003, 9(6), 685-693.
16. Jain, R. K.; Booth, M. F. What brings pericytes to tumor vessels? J. Clin. Invest., 2003, 112(8), 1134-1136.
17. Hellstrom, M.; Kalen, M.; Lindahl, P.; Abramsson, A.; Betsholtz, C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development, 1999, 126(14), 3047-3055.
18. Abramsson, A.; Lindblom, P.; Betsholtz, C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest., 2003, 112(8), 1142-11451.
19. Lindblom, P.; Gerhardt, H.; Liebner, S.; Abramsson, A.; Enge, M.; Hellstrom, M.; Backstrom, G.; Fredriksson, S.; Landegren, U.; Nystrom, H. C.; Bergstrom, G.; Dejana, E.; Ostman, A.; Lindahl, P.; Betsholtz, C. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev., 2003, 17(15), 1835-1840.
20. van Hinsbergh, V. W.; Koolwijk, P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res., 2008, 78(2), 203-212.
21. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T. H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2000, 2(10), 737-744.
22. Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wallasch, C.; Ullrich, A. EGF receptor transactivation by Gprotein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature, 1999, 402(6764), 884-888.
23. Langlois, S.; Gingras, D.; Beliveau, R. Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood, 2004, 103(8), 3020-3028.
24. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer, 2008, 8(8), 604-617.
25. Eliceiri, B. P.; Klemke, R.; Stromblad, S.; Cheresh, D. A. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol., 1998, 140(5), 1255-1263.
26. Brooks, P. C.; Montgomery, A. M.; Rosenfeld, M.; Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994, 79(7), 1157-1164.
27. Kim, S.; Bell, K.; Mousa, S. A.; Varner, J. A. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol., 2000, 156(4), 1345-1362.
28. Ellis, L. M.; Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer, 2008, 8(8), 579-591.
29. Ferrara, N.; Gerber, H. P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-676.
30. Carmeliet, P.; Ferreira, V.; Breier, G.; Pollefeyt, S.; Kieckens, L.; Gertsenstein, M.; Fahrig, M.; Vandenhoeck, A.; Harpal, K.; Eberhardt, C.; Declercq, C.; Pawling, J.; Moons, L.; Collen, D.; Risau, W.; Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996, 380(6573), 435-439.
31. Leung, D. W.; Cachianes, G.; Kuang, W. J.; Goeddel, D. V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246(4935), 1306-1309.
32. Gerber, H. P.; Condorelli, F.; Park, J.; Ferrara, N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem., 1997, 272(38), 23659-23667.
33. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 1997, 18(1), 4-25.
34. Tsuzuki, Y.; Fukumura, D.; Oosthuyse, B.; Koike, C.; Carmeliet, P.; Jain, R. K. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res., 2000, 60(22), 6248-6252.
35. Soker, S.; Takashima, S.; Miao, H. Q.; Neufeld, G.; Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 1998, 92(6), 735-745.
36. Murga, M.; Fernandez-Capetillo, O.; Tosato, G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood, 2005, 105(5), 1992-1999.
37. Cao, Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal, 2009, 2(59), re1.
38. Semenza, G. L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev., 2000, 19(1-2), 59-65.
39. Gupta, K.; Kshirsagar, S.; Li, W.; Gui, L.; Ramakrishnan, S.; Gupta, P.; Law, P. Y.; Hebbel, R. P. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp. Cell Res., 1999, 247(2), 495-504.
40. Nor, J. E.; Christensen, J.; Liu, J.; Peters, M.; Mooney, D. J.; Strieter, R. M.; Polverini, P. J. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res., 2001, 61(5), 2183-2188.
41. Loughna, S.; Sato, T. N. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol., 2001, 20(5-6), 319-325.
42. Singh, H.; Milner, C. S.; Aguilar Hernandez, M. M.; Patel, N.; Brindle, N. P. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases. Cell Signal, 2009, 21(8), 1346-1350.
43. Maisonpierre, P. C.; Suri, C.; Jones, P. F.; Bartunkova, S.; Wiegand, S. J.; Radziejewski, C.; Compton, D.; McClain, J.; Aldrich, T. H.; Papadopoulos, N.; Daly, T. J.; Davis, S.; Sato, T. N.; Yancopoulos, G. D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 1997, 277(5322), 55-60.
44. Findley, C. M.; Cudmore, M. J.; Ahmed, A.; Kontos, C. D. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler. Thromb. Vasc. Biol., 2007, 27(12), 2619-2626.
45. Weidner, N.; Semple, J. P.; Welch, W. R.; Folkman, J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N. Engl. J. Med., 1991, 324(1), 1-8.
46. Weidner, N.; Folkman, J.; Pozza, F.; Bevilacqua, P.; Allred, E. N.; Moore, D. H.; Meli, S.; Gasparini, G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst., 1992, 84(24), 1875-1887.
47. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1(1), 27-31.
48. Imao, T.; Egawa, M.; Takashima, H.; Koshida, K.; Namiki, M. Inverse correlation of microvessel density with metastasis and prognosis in renal cell carcinoma. Int. J. Urol., 2004, 11(11), 948-953.
49. Busam, K. J.; Berwick, M.; Blessing, K.; Fandrey, K.; Kang, S.; Karaoli, T.; Fine, J.; Cochran, A. J.; White, W. L.; Rivers, J. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am. J. Pathol., 1995, 147(4), 1049-1056.
50. Carnochan, P.; Briggs, J. C.; Westbury, G.; Davies, A. J. The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br. J. Cancer, 1991, 64(1), 102-107.
51. Neitzel, L. T.; Neitzel, C. D.; Magee, K. L.; Malafa, M. P. Angiogenesis correlates with metastasis in melanoma. Ann. Surg. Oncol., 1999, 6(1), 70-74.
52. Heymans, O.; Blacher, S.; Brouers, F.; Pierard, G. E. Fractal quantification of the microvasculature heterogeneity in cutaneous melanoma. Dermatology, 1999, 198(2), 212-217.
53. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307(5706), 58-62.
54. Qian, C. N.; Huang, D.; Wondergem, B.; Teh, B. T. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer, 2009, 115(Suppl.10), 2282-2289.
55. Danielsen, T.; Rofstad, E. K. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int. J. Cancer, 1998, 76(6), 836-841.
56. Graells, J.; Vinyals, A.; Figueras, A.; Llorens, A.; Moreno, A.; Marcoval, J.; Gonzalez, F. J.; Fabra, A. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J. Invest. Dermatol., 2004, 123(6), 1151-1161.
57. Potti, A.; Moazzam, N.; Tendulkar, K.; Javed, N. A.; Koch, M.; Kargas, S. Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. Anticancer Res., 2003, 23(5A), 4023-4026.
58. Simonetti, O.; Lucarini, G.; Brancorsini, D.; Nita, P.; Bernardini, M. L.; Biagini, G.; Offidani, A. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer, 2002, 95(9), 1963-19670.
59. Goydos, J. S.; Gorski, D. H. Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clin. Cancer Res., 2003, 9(16 Pt 1), 5962-5967.
60. Ugurel, S.; Rappl, G.; Tilgen, W.; Reinhold, U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol., 2001, 19(2), 577-583.
61. Osella-Abate, S.; Quaglino, P.; Savoia, P.; Leporati, C.; Comessatti, A.; Bernengo, M. G. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res., 2002, 12(4), 325-334.
62. Mehnert, J. M.; McCarthy, M. M.; Jilaveanu, L.; Flaherty, K. T.; Aziz, S.; Camp, R. L.; Rimm, D. L.; Kluger, H. M. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum. Pathol., 2010, 41(3), 375-384.
63. Mouawad, R.; Spano, J. P.; Comperat, E.; Capron, F.; Khayat, D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur. J. Cancer, 2009, 45(8), 1407-1414.
64. Helfrich, I.; Edler, L.; Sucker, A.; Thomas, M.; Christian, S.; Schadendorf, D.; Augustin, H. G. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res., 2009, 15(4), 1384-1392.
65. Rundhaug, J. E. Matrix metalloproteinases and angiogenesis. J. Cell Mol. Med., 2005, 9(2), 267-285.
66. Hofmann, U. B.; Westphal, J. R.; Van Muijen, G. N.; Ruiter, D. J. Matrix metalloproteinases in human melanoma. J. Invest. Dermatol., 2000, 115(3), 337-344.
67. Nikkola, J.; Vihinen, P.; Vuoristo, M. S.; Kellokumpu-Lehtinen, P.; Kahari, V. M.; Pyrhonen, S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res., 2005, 11(14), 5158-5166.
68. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2(3), 161-174.
69. Kerkela, E.; Saarialho-Kere, U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp. Dermatol., 2003, 12(2), 109-125.
70. Iida, J.; Wilhelmson, K. L.; Price, M. A.; Wilson, C. M.; Pei, D.; Furcht, L. T.; McCarthy, J. B. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J. Invest. Dermatol., 2004, 122(1), 167-176.
71. Seftor, R. E.; Seftor, E. A.; Koshikawa, N.; Meltzer, P. S.; Gardner, L. M.; Bilban, M.; Stetler-Stevenson, W. G.; Quaranta, V.; Hendrix, M. J. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res., 2001, 61(17), 6322-6327.
72. Hendrix, M. J.; Seftor, E. A.; Hess, A. R.; Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer, 2003, 3(6), 411-421.
73. Yana, I.; Sagara, H.; Takaki, S.; Takatsu, K.; Nakamura, K.; Nakao, K.; Katsuki, M.; Taniguchi, S.; Aoki, T.; Sato, H.; Weiss, S. J.; Seiki, M. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J. Cell Sci., 2007, 120(Pt 9), 1607-1614.
74. Sounni, N. E.; Roghi, C.; Chabottaux, V.; Janssen, M.; Munaut, C.; Maquoi, E.; Galvez, B. G.; Gilles, C.; Frankenne, F.; Murphy, G.; Foidart, J. M.; Noel, A. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J. Biol. Chem., 2004, 279(14), 13564-13574.
75. Sounni, N. E.; Devy, L.; Hajitou, A.; Frankenne, F.; Munaut, C.; Gilles, C.; Deroanne, C.; Thompson, E. W.; Foidart, J. M.; Noel, A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J., 2002, 16(6), 555-564.
76. Eskens, F. A. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br. J. Cancer, 2004, 90(1), 1-7.
77. Oku, T.; Tjuvajev, J. G.; Miyagawa, T.; Sasajima, T.; Joshi, A.; Joshi, R.; Finn, R.; Claffey, K. P.; Blasberg, R. G. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res., 1998, 58(18), 4185-4192.
78. Li, Y.; Wang, M. N.; Li, H.; King, K. D.; Bassi, R.; Sun, H.; Santiago, A.; Hooper, A. T.; Bohlen, P.; Hicklin, D. J. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med., 2002, 195(12), 1575-1584.
79. Kamba, T.; McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer, 2007, 96(12), 1788-1795.
80. Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer, 2006, 6(9), 714-727.
81. Ivy, S. P.; Wick, J. Y.; Kaufman, B. M. An overview of smallmolecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol., 2009, 6(10), 569-579.
82. Chen, H. X.; Cleck, J. N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol., 2009, 6(8), 465-77.
83. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 2001, 7(9), 987-989.
84. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342.
85. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355(24), 2542-2550.
86. 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol., 2007, 25(12), 1539-1544.
87. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E. A.; Shenkier, T.; Cella, D.; Davidson, N. E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med., 2007, 357(26), 2666-2676.
88. 3rd. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol., 2007, 14(8), 2367-2376.
89. Perez, D. G.; Suman, V. J.; Fitch, T. R.; Amatruda, T., 3rd; Morton, R. F.; Jilani, S. Z.; Constantinou, C. L.; Egner, J. R.; Kottschade, L. A.; Markovic, S. N. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer, 2009, 115(1), 119-127.
90. O'Day, S.; Kim, K.; J Sosman; Peterson, A.; Feng, S.; Minor, D.; Fruehauf, J.; Linette, G.; Markovic, S.; Carson, W. A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma. Eur. J. Cancer Suppl., 2009, 7(Suppl. 3), 23LBA.
91. Boasberg, P.; Cruickshank, S.; Hamid, O.; O'Day, S.; Weber, R.; Spitler, L. Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma.J. Clin. Onc., 2009, 27(Suppl.15), Abstract 9061.
92. th World Congress on Melanoma 5th Congress of the European Association of Dermato-Oncology (EADO): Final Program. May 12-16 Vienna, Austria 2009, pp237.
93. Jain, R. K.; Xu, L. alphaPlGF: a new kid on the antiangiogenesis block. Cell, 2007, 131(3), 443-445.
94. Lacal, P. M.; Failla, C. M.; Pagani, E.; Odorisio, T.; Schietroma, C.; Falcinelli, S.; Zambruno, G.; D'Atri, S. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J. Invest. Dermatol., 2000, 115(6), 1000-1007.
95. Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; De Mol, M.; Autiero, M.; Wyns, S.; Plaisance, S.; Moons, L.; van Rooijen, N.; Giacca, M.; Stassen, J. M.; Dewerchin, M.; Collen, D.; Carmeliet, P. Anti-PlGF inhibits growth of VEGF(R)-inhibitorresistant tumors without affecting healthy vessels. Cell, 2007, 131(3), 463-475.
96. Spratlin, J. L.; Cohen, R. B.; Eadens, M.; Gore, L.; Camidge, D. R.; Diab, S.; Leong, S.; O'Bryant, C.; Chow, L. Q.; Serkova, N. J.; Meropol, N. J.; Lewis, N. L.; Chiorean, E. G.; Fox, F.; Youssoufian, H.; Rowinsky, E. K.; Eckhardt, S. G. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol., 2010, 28(5), 780-787.
97. Krupitskaya, Y.; Wakelee, H. A. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr. Opin. Investig. Drugs, 2009, 10(6), 597-605.
98. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S. D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.; Rudge, J. S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA, 2002, 99(17), 11393-11398.
99. Tarhini, A.; Christensen, S.; Frankel, P.; Margolin, K.; Ruel, C.; Shipe-Spotloe, J.; DeMark, M.; Kirkwood, J. Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J. Clin. Onc., 2009, 27(Suppl. 15), Abstract 9028.
100. Lawrence, D. S.; Niu, J. Protein kinase inhibitors: the tyrosinespecific protein kinases. Pharmacol. Ther., 1998, 77(2), 81-114.
101. Borzilleri, R. M.; Zheng, X.; Qian, L.; Ellis, C.; Cai, Z. W.; Wautlet, B. S.; Mortillo, S.; Jeyaseelan, R., Sr.; Kukral, D. W.; Fura, A.; Kamath, A.; Vyas, V.; Tokarski, J. S.; Barrish, J. C.; Hunt, J. T.; Lombardo, L. J.; Fargnoli, J.; Bhide, R. S. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triaz ines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J. Med. Chem., 2005, 48(12), 3991-4008.
102. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factorinduced responses and tumor growth after oral administration. Cancer Res., 2000, 60(8), 2178-2189.
103. Cook, N.; Basu, B.; Biswas, S.; Kareclas, P.; Mann, C.; Palmer, C.; Thomas, A.; Nicholson, S.; Morgan, B.; Lomas, D.; Sirohi, B.; Mander, A. P.; Middleton, M.; Corrie, P. G. A phase 2 study of vatalanib in metastatic melanoma patients. Eur. J. Cancer, 2010, 46(15), 2671-2673.
104. Stopeck, A.; Sheldon, M.; Vahedian, M.; Cropp, G.; Gosalia, R.; Hannah, A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res., 2002, 8(9), 2798-2805.
105. Fong, T. A.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 1999, 59(1), 99-106.
106. Kuenen, B. C.; Tabernero, J.; Baselga, J.; Cavalli, F.; Pfanner, E.; Conte, P. F.; Seeber, S.; Madhusudan, S.; Deplanque, G.; Huisman, H.; Scigalla, P.; Hoekman, K.; Harris, A. L. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res., 2003, 9(5), 1648-1655.
107. Chow, L. Q.; Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol., 2007, 25(7), 884-896.
108. Decoster, L.; Neyns, B.; Broek, I. V.; Anckaert, E.; Clerck, D. D.; Mey, J. D.; Majois, F.; Baurain, J.; Denys, H.; Greve, J. D. Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. J. Clin. Oncol., 2010, 28(Suppl. 15), 8518.
109. Mizukami, Y.; Kohgo, Y.; Chung, D. C. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin. Cancer Res., 2007, 13(19), 5670-5674.
110. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70(3), 461-477.
111. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116(6), 855-867.
112. Flaherty, K. T.; Schiller, J.; Schuchter, L. M.; Liu, G.; Tuveson, D. A.; Redlinger, M.; Lathia, C.; Xia, C.; Petrenciuc, O.; Hingorani, S. R.; Jacobetz, M. A.; Van Belle, P. A.; Elder, D.; Brose, M. S.; Weber, B. L.; Albertini, M. R.; O'Dwyer, P. J. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res., 2008, 14(15), 4836-4842.
113. Voliotis, D.; Dumas, J. Clinical Development of Sorafenib (BAY 43-9006) VEGFR and RAF Inhibitor. In: Tumor Angiogenesis:Basic Mechanisms and Cancer Therapy; Marme D.; Fusenig N. Eds; Springer Berlin Heidelberg: New York, 2008, pp 655-669.
114. Hauschild, A.; Agarwala, S. S.; Trefzer, U.; Hogg, D.; Robert, C.; Hersey, P.; Eggermont, A.; Grabbe, S.; Gonzalez, R.; Gille, J.; Peschel, C.; Schadendorf, D.; Garbe, C.; O'Day, S.; Daud, A.; White, J. M.; Xia, C.; Patel, K.; Kirkwood, J. M.; Keilholz, U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as secondline treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol., 2009, 27(17), 2823-2830.
115. McDermott, D. F.; Sosman, J. A.; Gonzalez, R.; Hodi, F. S.; Linette, G. P.; Richards, J.; Jakub, J. W.; Beeram, M.; Tarantolo, S.; Agarwala, S.; Frenette, G.; Puzanov, I.; Cranmer, L.; Lewis, K.; Kirkwood, J.; White, J. M.; Xia, C.; Patel, K.; Hersh, E. Doubleblind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol., 2008, 26(13), 2178-2185.
116. Amaravadi, R. K.; Schuchter, L. M.; McDermott, D. F.; Kramer, A.; Giles, L.; Gramlich, K.; Carberry, M.; Troxel, A. B.; Letrero, R.; Nathanson, K. L.; Atkins, M. B.; O'Dwyer, P. J.; Flaherty, K. T. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin. Cancer Res., 2009, 15(24), 7711-7718.
117. Middleton, M. R.; Grob, J. J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; Dreno, B.; Henz, M.; Schadendorf, D.; Kapp, A.; Weiss, J.; Fraass, U.; Statkevich, P.; Muller, M.; Thatcher, N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol., 2000, 18(1), 158-166.
118. Robert, C.; Lazar, V.; Lacroix, L.; Farace, F.; Lassau, N.; Dromain, C.; Poirier, V.; Zitvogel, L.; Soria, J.; Mateus, C. Phase I/II study of the association of sorafenib and temozolomide (extended schedule) in patients with metastatic melanoma: A new clinical response profile with massive tumor necroses. J. Clin. Oncol., 2009, 27 (Suppl.15), Abstract 9062.
119. Egberts, F.; Gutzmer, R.; Ugurel, S.; Becker, J. C.; Trefzer, U.; Degen, A.; Schenck, F.; Frey, L.; Wilhelm, T.; Hassel, J. C.; Schadendorf, D.; Livingstone, E.; Mauch, C.; Garbe, C.; Berking, C.; Rass, K.; Mohr, P.; Kaehler, K. C.; Weichenthal, M.; Hauschild, A. Sorafenib and pegylated interferon-alpha2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann. Oncol., 2011, 22(7), 1667-1674.
120. Kim, K.; Saro, J.; Moschos, S.; Hwu, P.; Tarhini, A.; Hwu, W.; Jones, G.; Wang, Y.; Rupani, H.; Kirkwood, J. A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma. J. Clin. Oncol., 2008, 26 (Suppl. 15), Abstract 9026.
121. Liu, G.; Rugo, H. S.; Wilding, G.; McShane, T. M.; Evelhoch, J. L.; Ng, C.; Jackson, E.; Kelcz, F.; Yeh, B. M.; Lee, F. T., Jr.; Charnsangavej, C.; Park, J. W.; Ashton, E. A.; Steinfeldt, H. M.; Pithavala, Y. K.; Reich, S. D.; Herbst, R. S. Dynamic contrastenhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol., 2005, 23(24), 5464-5473.
122. Hu-Lowe, D. D.; Zou, H. Y.; Grazzini, M. L.; Hallin, M. E.; Wickman, G. R.; Amundson, K.; Chen, J. H.; Rewolinski, D. A.; Yamazaki, S.; Wu, E. Y.; McTigue, M. A.; Murray, B. W.; Kania, R. S.; O'Connor, P.; Shalinsky, D. R.; Bender, S. L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res., 2008, 14(22), 7272-7283.
123. Fruehauf, J.; Lutzky, J.; McDermott, D.; Brown, C.; Pithavala, Y.; Bycott, P.; Shalinsky, D.; Liau, K.; Niethammer, A.; Rixe, O. Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study. J. Clin. Oncol., 2008, 26(Suppl.15), Abstract 9006
124. Rini, B.; Scjiller, J.; Fruehauf, J.; Cohen, E.; Tarazi, J.; Rosbrook, B.; Ricart, A.; Olszanski, A.; Kim, S.; Spano, J. Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J. Clin. Oncol., 2008, 26(Suppl. 15), Abstract 3543.
125. Chirivi, R. G.; Garofalo, A.; Crimmin, M. J.; Bawden, L. J.; Stoppacciaro, A.; Brown, P. D.; Giavazzi, R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 1994, 58(3), 460-464.
126. Quirt, I.; Bodurth, A.; Lohmann, R.; Rusthoven, J.; Belanger, K.; Young, V.; Wainman, N.; Stewar, W.; Eisenhauer, E. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs, 2002, 20(4), 431-437.
127. Palavalli, L. H.; Prickett, T. D.; Wunderlich, J. R.; Wei, X.; Burrell, A. S.; Porter-Gill, P.; Davis, S.; Wang, C.; Cronin, J. C.; Agrawal, N. S.; Lin, J. C.; Westbroek, W.; Hoogstraten-Miller, S.; Molinolo, A. A.; Fetsch, P.; Filie, A. C.; O'Connell, M. P.; Banister, C. E.; Howard, J. D.; Buckhaults, P.; Weeraratna, A. T.; Brody, L. C.; Rosenberg, S. A.; Samuels, Y. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat. Genet., 2009, 41(5),518-520
128. Pavlaki, M.; Zucker, S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev., 2003, 22(2-3), 177-203.
129. Gutheil, J. C.; Campbell, T. N.; Pierce, P. R.; Watkins, J. D.; Huse, W. D.; Bodkin, D. J.; Cheresh, D. A. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin. Cancer Res., 2000, 6(8), 3056-3061.
130. Hersey, P.; Sosman, J.; O'Day, S.; Richards, J.; Bedikian, A.; Gonzalez, R.; Sharfman, W.; Weber, R.; Logan, T.; Buzoianu, M.; Hammershaimb, L.; Kirkwood, J. M. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or-dacarbazine in patients with stage IV metastatic melanoma. Cancer, 2010, 116(6), 1526-1534.
131. Schadendorf, D.; Algarra, S. M.; Bastholt, L.; Cinat, G.; Dreno, B.; Eggermont, A. M.; Espinosa, E.; Guo, J.; Hauschild, A.; Petrella, T.; Schachter, J.; Hersey, P. Immunotherapy of distant metastatic disease. Ann. Oncol., 2009, 20 (Suppl. 6), 41-50.
132. Trikha, M.; Zhou, Z.; Nemeth, J. A.; Chen, Q.; Sharp, C.; Emmell, E.; Giles-Komar, J.; Nakada, M. T. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer, 2004, 110(3), 326-335.
133. Mullamitha, S. A.; Ton, N. C.; Parker, G. J.; Jackson, A.; Julyan, P. J.; Roberts, C.; Buonaccorsi, G. A.; Watson, Y.; Davies, K.; Cheung, S.; Hope, L.; Valle, J. W.; Radford, J. A.; Lawrance, J.; Saunders, M. P.; Munteanu, M. C.; Nakada, M. T.; Nemeth, J. A.; Davis, H. M.; Jiao, Q.; Prabhakar, U.; Lang, Z.; Corringham, R. E.; Beckman, R. A.; Jayson, G. C. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res., 2007, 13(7), 2128-2135.
134. O'Day, S.; Pavlick, A.; Loquai, C.; Lawson, D.; Gutzmer, R.; Richards, J.; Schadendorf, D.; Thompson, J. A.; Gonzalez, R.; Trefzer, U.; Mohr, P.; Ottensmeier, C.; Chao, D.; Zhong, B.; de Boer, C. J.; Uhlar, C.; Marshall, D.; Gore, M. E.; Lang, Z.; Hait, W.; Ho, P. A randomised, phase II study of intetumumab, an antialpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br. J. Cancer, 2011, 105(3), 346-352.
135. Tentori, L.; Dorio, A. S.; Muzi, A.; Lacal, P. M.; Ruffini, F.; Navarra, P.; Graziani, G. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol. Rep., 2008, 19(4), 1039-1043.
136. Kim, K.; Diwan, A.; Papadopoulos, N.; Bedikian, A.; Camacho, L.; Hwu, P.; Johnson, M.; Colevas, A.; Prieto, V. A randomized phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM). J. Clin. Oncol., 2007, 25(Suppl.18), Abstract 8548.
137. Kuwada, S. K. Drug evaluation: Volociximab, an angiogenesisinhibiting chimeric monoclonal antibody. Curr. Opin. Mol. Ther., 2007, 9(1), 92-98.
138. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88(2), 277-285.
139. Ling, Y.; Yang, Y.; Lu, N.; You, Q. D.; Wang, S.; Gao, Y.; Chen, Y.; Guo, Q. L. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem. Biophys. Res. Commun., 2007, 361(1), 79-84.
140. Abdollahi, A.; Hahnfeldt, P.; Maercker, C.; Grone, H. J.; Debus, J.; Ansorge, W.; Folkman, J.; Hlatky, L.; Huber, P. E. Endostatin's antiangiogenic signaling network. Mol. Cell, 2004, 13(5), 649-463.
141. Fu, Y.; Tang, H.; Huang, Y.; Song, N.; Luo, Y. Unraveling the mysteries of endostatin. IUBMB. Life, 2009, 61(6), 613-626.
142. Yang, L.; Wang, J.; Tang, Z.; Liu, X.; Huang, J.; Li, S.; Dong, Y.; Zhang, H.; Xue, L.; Chu, D.; Sun, Y. A phase I clinical trial for recombinant human endostatin. Chinese J. New Drugs, 2004, 13, 6.
143. Cui, C.; Chi, Z.; Yuan, X.; Si, L.; Sheng, X.; Shen, L.; J, J. G. Endostatin combined with chemotherapy as first-line therapy for stage IV melanoma patients: A phase II clinical study. J. Clin. Oncol., 2009, 27(Suppl. 15), Abstract e20003.
144. Hwu, W. J.; Krown, S. E.; Menell, J. H.; Panageas, K. S.; Merrell, J.; Lamb, L. A.; Williams, L. J.; Quinn, C. J.; Foster, T.; Chapman, P. B.; Livingston, P. O.; Wolchok, J. D.; Houghton, A. N. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol., 2003, 21(17), 3351-3356.
145. Clark, J. I.; Moon, J.; Hutchins, L. F.; Sosman, J. A.; Kast, W. M.; Da Silva, D. M.; Liu, P. Y.; Thompson, J. A.; Flaherty, L. E.; Sondak, V. K. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer, 2010, 116(2), 424-431.
146. Danson, S.; Lorigan, P.; Arance, A.; Clamp, A.; Ranson, M.; Hodgetts, J.; Lomax, L.; Ashcroft, L.; Thatcher, N.; Middleton, M. R. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol., 2003, 21(13), 2551-2557.
147. Eisen, T.; Trefzer, U.; Hamilton, A.; Hersey, P.; Millward, M.; Knight, R. D.; Jungnelius, J. U.; Glaspy, J. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer, 2010, 116(1), 146-154.
148. Patnaik, A.; Chiorean, E.; Tolcher, A.; Papadopoulos, K.; Beeram, M.; Kee, D.; Waddell, M.; Gilles, E.; Buchbinder, A. EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. J. Clin. Oncol. 2009, 27(Suppl.15), Abstract 2564.
149. Hewitson, K. S.; Schofield, C. J. The HIF pathway as a therapeutic target. Drug Discov. Today, 2004, 9(16), 704-711.
150. Semenza, G. L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today, 2007, 12(19-20), 853-859.
151. Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett., 2009, 280(2), 145-153.
152. Howell, P. M., Jr.; Liu, S.; Ren, S.; Behlen, C.; Fodstad, O.; Riker, A. I. Epigenetics in human melanoma. Cancer Control, 2009, 16(3), 200-218.
153. Rossig, L.; Li, H.; Fisslthaler, B.; Urbich, C.; Fleming, I.; Forstermann, U.; Zeiher, A. M.; Dimmeler, S. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res., 2002, 91(9), 837-844.
154. Sasakawa, Y.; Naoe, Y.; Inoue, T.; Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol., 2002, 64(7), 1079-1090.
155. Liu, T.; Kuljaca, S.; Tee, A.; Marshall, G. M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev., 2006, 32(3), 157-165.
156. Hess-Stumpp, H.; Bracker, T. U.; Henderson, D.; Politz, O. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. Int. J. Biochem. Cell Biol., 2007, 39(7-8), 1388-1405.
157. Hauschild, A.; Trefzer, U.; Garbe, C.; Kaehler, K. C.; Ugurel, S.; Kiecker, F.; Eigentler, T.; Krissel, H.; Schott, A.; Schadendorf, D. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res., 2008, 18(4), 274-278.
158. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S. T.; Chen, I.; Bycott, P. W.; Baum, C. M.; Figlin, R. A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356(2), 115-124.
159. Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J. O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007, 370(9605), 2103-2111.
160. Kerbel, R.; Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2002, 2(10), 727-739.
161. Gourley, M.; Williamson, J. S. Angiogenesis: new targets for the development of anticancer chemotherapies. Curr. Pharm. Des., 2000, 6(4), 417-439.
162. Jain, R. K.; Duda, D. G.; Willett, C. G.; Sahani, D. V.; Zhu, A. X.; Loeffler, J. S.; Batchelor, T. T.; Sorensen, A. G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol., 2009, 6(6), 327-338.
163. Murukesh, N.; Dive, C.; Jayson, G. C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer, 2010, 102(1), 8-18.
164. Wyman, K.; Spigel, D.; Puzanov, I.; Hainsworth, J.; Kelley, M.; Krozely, P.; Sturgeon, D.; Sosman, J. A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. J. Clin. Oncol., 2007, 25(Suppl.18), Abstract 8539.
165. McClay, E.; Bessudo, A.; Frakes, L.; Eisenberg, S.; Just, R.; Banerjee, P.; Sinclair, J. A phase I/II trial of the combination of bevacizumab, oxaliplatin, and sorafenib in patients with metastatic melanoma. J. Clin. Oncol., 2008, 26(Suppl.15), Abstract 20020.
166. Gonzalez-Cao, M.; Viteri, S.; Diaz-Lagares, A.; Gonzalez, A.; Redondo, P.; Nieto, Y.; Espinos, J.; Chopitea, A.; Ponz, M.; Martin-Algarra, S. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology, 2008, 74(1-2), 12-16.
167. Si, L.; Han, M.; Chi, Z.; Cui, C.; Sheng, X.; Li, S.; Kong, Y.; Guo, J. Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma. J. Clin. Oncol., 2010, 28(Suppl.15), Abstract 8564.
168. Hainsworth, J. D.; Infante, J. R.; Spigel, D. R.; Peyton, J. D.; Thompson, D. S.; Lane, C. M.; Clark, B. L.; Rubin, M. S.; Trent, D. F.; Burris, H. A., 3rd Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer, 2010, 116(17), 4122-4129.
169. Munzone, E.; Testori, A.; Minchella, I.; Mosconi, M.; Passoni, C.; Verri, E.; Rocca, M. C.; Lambiase, A.; Goldhirsch, A.; Nolè, F. A phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma. J. Clin. Oncol, 2007, 25(Suppl.18), Abstract 8579.
170. Vihinen, P. P.; Hernberg, M.; Vuoristo, M. S.; Tyynela, K.; Laukka, M.; Lundin, J.; Ivaska, J.; Pyrhonen, S. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferonalpha2a as first line treatment in metastatic melanoma. Melanoma Res., 2010, 20(4), 318-325.
171. Moos, R. V.; Seifert, B.; Ochsenbein, A.; Cathomas, R.; Schläppi, M.; Gillessen, S.; Schuller, J.; Michielin, O.; Goldinger, S.; Dummer, R. 24LBA Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). Eur. J. Cancer Suppl., 2009, 7(Suppl.3), 13-14.
172. Eisen, T.; Ahmad, T.; Flaherty, K. T.; Gore, M.; Kaye, S.; Marais, R.; Gibbens, I.; Hackett, S.; James, M.; Schuchter, L. M.; Nathanson, K. L.; Xia, C.; Simantov, R.; Schwartz, B.; Poulin-Costello, M.; O'Dwyer, P. J.; Ratain, M. J. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer, 2006, 95(5), 581-586.
173. Eisen, T.; Marais, R.; Affolter, A.; Lorigan, P.; Robert, C.; Corrie, P.; Ottensmeier, C.; Chevreau, C.; Chao, D.; Nathan, P. D.; Jouary, T.; Harries, M.; Negrier, S.; Montegriffo, E.; Ahmad, T.; Gibbens, I.; James, M. G.; Strauss, U. P.; Prendergast, S.; Gore, M. E. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br. J. Cancer, 2011, 105(3), 353-359.
174. Kim, K.; Davies, M.; Papadapoulos, N.; Bedikian, A.; Hwu, Y.; Woodard, K.; Washington, E.; Dancey, J.; Wright, J.; Hwu, P. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. J. Clin. Oncol., 2009, 27(Suppl. 15), Abstract 9026.
175. Barton, J. A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma. J. Clin. Oncol., 2008, 26(Suppl.15), Abstract 9051.
176. Cranmer, L.; Bedikian, A.; Ribas, A.; O'Day, S.; Forero-Torres, A.; Yazji, S.; Kirkwood, J. Phase II study of volociximab (M200), an {alpha}5ß1 anti-integrin antibody in metastatic melanoma. J. Clin. Oncol., 2006, 24(Suppl.18), Abstract 8011.
177. Joseph, R.; Prieto, V.; Papadopolus, N.; Bedikian, A.; Colevas, A.; Kim, K. In vivo molecular changes in patients (pts) with metastatic melanoma treated with EMD121974 (selective antagonist of avβ3 integrin). J. Clin. Oncol., 2009, 27(Suppl. 15), Abstract 9058.
178. Smolich, B. D.; Yuen, H. A.; West, K. A.; Giles, F. J.; Albitar, M.; Cherrington, J. M. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001, 97(5), 1413-1421.
179. Giles, F. J.; Stopeck, A. T.; Silverman, L. R.; Lancet, J. E.; Cooper, M. A.; Hannah, A. L.; Cherrington, J. M.; O'Farrell, A. M.; Yuen, H. A.; Louie, S. G.; Hong, W.; Cortes, J. E.; Verstovsek, S.; Albitar, M.; O'Brien, S. M.; Kantarjian, H. M.; Karp, J. E. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood, 2003, 102(3), 795-801.
180. Abrams, T. J.; Lee, L. B.; Murray, L. J.; Pryer, N. K.; Cherrington, J. M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther., 2003, 2(5), 471-478.
181. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64(19), 7099-7109.
182. Rini, B. I. SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin. Genitourin. Cancer, 2005, 4(3), 175-180.
183. Lee, S. H.; Lopes de Menezes, D.; Vora, J.; Harris, A.; Ye, H.; Nordahl, L.; Garrett, E.; Samara, E.; Aukerman, S. L.; Gelb, A. B.; Heise, C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res., 2005, 11(10), 3633-3641.